Bionomics (NASDAQ:BNOX) Shares Up 4.2% – Here’s Why

Bionomics Limited (NASDAQ:BNOX)’s share price rose 4.2% during mid-day trading on Friday . The company traded as high as $0.29 and last traded at $0.25. Approximately 6,835,891 shares were traded during trading, an increase of 140% from the average daily volume of 2,848,698 shares. The stock had previously closed at $0.24.

Analysts Set New Price Targets

Separately, William Blair reiterated an “outperform” rating on shares of Bionomics in a research note on Friday, November 15th.

Bionomics Stock Performance

The business has a 50-day moving average of $0.29 and a two-hundred day moving average of $0.47.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bionomics stock. Armistice Capital LLC bought a new stake in Bionomics Limited (NASDAQ:BNOX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned approximately 15.03% of Bionomics as of its most recent filing with the Securities and Exchange Commission (SEC). 15.90% of the stock is currently owned by institutional investors.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.